Decision‐tree approach to the immunophenotype‐based prognosis of the B‐cell chronic lymphocytic leukemia
暂无分享,去创建一个
N. Masic | B. Jakšić | A Gagro | G Dasić | A Sabioncello | S Rabatić | B Vitale | N Masić | B Jaksić | A. Gagro | S. Rabatić | A. Sabioncello | G. Dašić | B. Vitale
[1] J. Cawley,et al. Heterogeneity of CLL: high CD23 antigen and αIFN receptor expression are features of favourable disease and of cell activation , 1988, British journal of haematology.
[2] R. Jones,et al. CD45RO+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic leukaemia B-cells. , 1995, Leukemia & lymphoma.
[3] F. Caligaris‐cappio. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. , 1996, Blood.
[4] C. Borrebaeck,et al. Human CD4+ T cells expressing CD45RA acquire the lymphokine gene expression of CD45RO+ T-helper cells after activation in vitro. , 1992, Immunology.
[5] J. Cawley,et al. CD23 ANTIGEN EXPRESSION IN CLL , 1989, British journal of haematology.
[6] H. Nielsen,et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. , 1991 .
[7] R. Weiss,et al. Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. , 1993, Blood.
[8] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[9] D. Hamann,et al. Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms. , 1996, Blood.
[10] E. Montserrat,et al. Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System , 1981 .
[11] C. Gasche,et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Reilly,et al. LACK OF CORRELATION BETWEEN CELL SURFACE ACTIVATION ANTIGEN EXPRESSION AND CLINICAL STAGE IN B‐CLL , 1989, British journal of haematology.
[13] B. Jakšić,et al. Total Tumour Mass Score (TTM): a New Parameter in Chronic Lymphocytic Leukaemia , 1981, British journal of haematology.
[14] J. Ross Quinlan,et al. C4.5: Programs for Machine Learning , 1992 .
[15] J. Bonnefoy,et al. CD23 and B-cell activation. , 1995, Current opinion in immunology.
[16] M. Grever,et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group , 1988, American journal of hematology.
[17] S. Fournier,et al. Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. , 1994, Blood.
[18] K. Foon,et al. Chronic lymphocytic leukemia: new insights into biology and therapy. , 1990, Annals of internal medicine.
[19] A. Gagro,et al. CD21‐CD23 ligand pair expression in children with allergic asthma , 1993, Clinical and Experimental Immunology.